Collaboration between medac and start-up chiron to develop organ-on-chip technology

Further development and establishment of animal free testing methods for the pharmaceutical industry

12-Nov-2024
Computer-generated image

The cooperation between medac and chiron presents a meaningful step towards a forward-looking development of alternative methods for animal free drug development (symbolic image).

Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical company medac and the start-up chiron biotechnology are working together on the further development and establishment of animal free testing methods for the pharmaceutical industry.

Animal testing still has a role for medical research and the development of therapies. Due to legal requirements animal testing is an obligatory part of pharmaceutical development and drug approval. Nevertheless, ethical aspects of animal testing as well as the question of their replacement through other testing methods are being discussed and challenged continuously.

The global pharmaceutical company medac located in Wedel and the Dutch start-up chiron biotechnology are working together for the further development and establishment of animal free testing methods for the pharmaceutical industry.

chiron has developed an advanced organ-on chip technology, which comprises placing of human cells on chips - eg. cells present in the joint - to test the efficacy of drugs. This ground-breaking technology has the potential to be a future alternative to animal testing in drug development.

The cooperation with medac includes testing if methotrexate – the gold standard for the treatment of rheumatoid arthritis - which could be used as a reference substance on the chips containing joint cells and to demonstrate the applicability of the method. As a reference substance Methotrexate should always show an effect under certain test conditions. Methotrexate would then serve as a reference for efficacy when new drugs are analysed. medac negotiated a master service agreement with chiron and provides methotrexate for further development of chiron’s technology.

Florian Ende, Head of Product Development at medac, commented on this cooperation: “With this cooperation medac makes an important contribution to the development and establishment of new approach methods (NAMs), which can be used for analysis of drug efficacy using human cells instead of performing animal studies.”

The cooperation between medac and chiron presents a meaningful step towards a forward-looking development of alternative methods for animal free drug development.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.